AI assistant
NovoCure Ltd — Director's Dealing 2017
May 4, 2017
31949_dirs_2017-05-04_60314f76-ad2b-4bb0-bd85-9b193f70a4ad.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Novocure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2017-05-02
Reporting Person: DOYLE WILLIAM F (Director, Executive Chairman)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-05-02 | Options to Buy Ordinary Shares | $11.85 | A | 881519 | Acquired | 2027-05-02 | Ordinary shares (881519) | Direct |
| 2017-05-02 | Options to Buy Ordinary Shares | $11.85 | A | 881519 | Acquired | 2027-05-02 | Ordinary shares (881519) | Direct |
| 2017-05-02 | Restricted Stock Unit | $ | A | 881519 | Acquired | Ordinary shares (881519) | Direct |
Footnotes
F1: Options to buy 881,519 ordinary shares will fully vest and become exercisable on May 2, 2020 if (i) the closing price of the Company's ordinary shares is at least $14.81 for a period of at least twenty (20) consecutive trading days at any time between May 2, 2017 and May 2, 2020 and (ii) Mr. Doyle has been continuously employed by the Company through May 2, 2020.
F2: Options to buy 881,519 ordinary shares will fully vest and become exercisable on May 2, 2022 if (i) the closing price of the Company's ordinary shares is at least $22.50 for a period of at least twenty (20) consecutive trading days at any time between May 2, 2017 and May 2, 2022 and (ii) Mr. Doyle has been continuously employed by the Company through May 2, 2022.
F3: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share.
F4: One-third of these restricted stock units are scheduled to vest on each of May 2, 2018, May 2, 2019, and May 2, 2020, subject to Mr. Doyle's continued employment through such dates.